EndoStream Medical Ltd., an Israeli innovator in neurovascular implant technology, has been acquired by Kaneka Corporation, a leading Japanese medical technology company, for $100 million. The acquisition represents the first significant biotech deal for Israel in 2025 and underscores the country’s prominence in medtech innovation.
Founded by CEO Daniel Mayer and CTO Alon May, EndoStream Medical has been at the forefront of neurovascular innovation. Their flagship device, Nautilus™, is a cutting-edge solution for the treatment of cerebral aneurysms. This minimally invasive implant is designed to address unmet medical needs, providing improved outcomes for patients suffering from life-threatening neurovascular conditions.
Kaneka Corporation emphasized the strategic importance of the acquisition in bolstering its neurovascular portfolio. The company projects global sales of Nautilus™ to reach $140 million (20 billion yen) over the next five years, reflecting the device’s market potential and its importance in advancing neurovascular healthcare.
This acquisition highlights Israel’s continued success as a hub for groundbreaking medical technologies. By integrating Nautilus™ into its offerings, Kaneka is poised to expand its presence in the neurovascular market and deliver transformative solutions to patients worldwide.
The landmark deal signals a strong start to 2025 for Israeli biotech, reinforcing the global appeal of the country’s innovative medtech solutions.
